Christiane Rordorf
Publications 41
#1Abhijit Chakraborty (Novartis)H-Index: 11
#2Stacey Tannenbaum (Novartis)H-Index: 7
Last.Sandip Roy (Novartis)H-Index: 4
view all 7 authors...
Canakinumab is a high-affinity human monoclonal anti-interleukin-1β (IL-1β) antibody of the IgG1/κ isotype designed to bind and neutralize the activity of human IL-1β, a pro-inflammatory cytokine. Canakinumab is currently being investigated on the premise that it would exert anti-inflammatory effects on a broad spectrum of diseases, driven by IL-1β. This paper focuses on the analysis of the pharmacokinetic and pharmacodynamic data from the canakinumab clinical development programme, describing r...
77 CitationsSource
#1Jasmin B. Kuemmerle-Deschner (Boston Children's Hospital)H-Index: 31
#2Eduardo RamosH-Index: 1
Last.Christiane Rordorf (Novartis)H-Index: 24
view all 11 authors...
Introduction Cryopyrin-associated periodic syndrome (CAPS) represents a spectrum of three auto-inflammatory syndromes, familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease/chronic infantile neurological cutaneous and articular syndrome (NOMID/CINCA) with etiology linked to mutations in the NLRP3 gene resulting in elevated interleukin-1β (IL-1β) release. CAPS is a rare hereditary auto-inflammatory disease, which may star...
70 CitationsSource
#1Helen J. LachmannH-Index: 57
#2Philip J. LoweH-Index: 22
Last.Thomas JungH-Index: 16
view all 12 authors...
The investigation of interleukin 1β (IL-1β) in human inflammatory diseases is hampered by the fact that it is virtually undetectable in human plasma. We demonstrate that by administering the anti–human IL-1β antibody canakinumab (ACZ885) to humans, the resulting formation of IL-1β–antibody complexes allowed the detection of in vivo–produced IL-1β. A two-compartment mathematical model was generated that predicted a constitutive production rate of 6 ng/d IL-1β in healthy subjects. In contrast, pat...
241 CitationsSource
#1Hans SkvaraH-Index: 8
#2Markus DawidH-Index: 1
Last.Thomas JungH-Index: 16
view all 20 authors...
PKC isoforms t, α, and β play fundamental roles in the activation of T cells and other immune cell functions. Here we show that the PKC inhibitor AEB071 both abolishes the production of several cytokines by activated human T cells, keratinocytes, and macrophages in vitro and inhibits an acute allergic contact dermatitis response in rats. To translate these findings into humans, single and multiple ascending oral doses of AEB071 were administered to healthy volunteers and patients with psoriasis,...
128 CitationsSource
#2Norbert BlankH-Index: 24
Last.Thomas Jung (Novartis)H-Index: 16
view all 10 authors...
This study was conducted to assess the efficacy, safety, and immunogenicity of canakinumab administered as a subcutaneous injection to patients with CAPS. Herein we report the results of 5 children (4–13 years) and 2 adolescents (16 and 17 years) enrolled in the study. All had documented NALP-3 gene mutations. Entry criteria were active disease evaluated by moderate to severe symptoms of CAPS (based on a 5 point global physician's assessment scale) and/or elevated CRP and SAA levels. The childre...
3 CitationsSource
#1N RupertoH-Index: 11
#2Pierre QuartierH-Index: 50
Last.Christiane Rordorf (Novartis)H-Index: 24
view all 10 authors...
Open Access Oral presentation 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA) N Ruperto*1, P Quartier2, N Wulffraat3, P Woo4, A Loy1, R Mouy2, B BaderMeunier2, B Prakken3, E Noseda5, C Rordorf5 and Martini for the Paediatric Rheumatology International Trials Organisation (PRINTO) A1
20 CitationsSource
#1Helmut WittkowskiH-Index: 28
Last.Dirk FoellH-Index: 48
view all 9 authors...
Background S100A12 is a member of the damage-associated molecular pattern molecules (DAMP) and expressed by activated granulocytes exhibiting its proinflammatory capacity by binding to the Receptor for Advanced Glycation Endproducts (RAGE). The aim of this study was to evaluate S100A12 in MWS patients before and during therapy with Anakinra (IL1Ra) and Canakinumab (a fully human monoclonal antibody against IL-1β).
#1Helen J. LachmannH-Index: 57
#2Thomas JungH-Index: 16
Last.Pn HawkinsH-Index: 29
view all 7 authors...
10 Citations
#1Rieke Alten (Charité)H-Index: 42
#2Hermann Gram (Novartis)H-Index: 33
Last.Thomas Jung (Novartis)H-Index: 16
view all 15 authors...
Introduction IL-1β is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Methods ACZ885, a fully human monoclonal antibody that neutralizes the bioactivity of human IL-1β, was generated to study the potent and long-lasting neutralization of IL-1β in mechanistic animal models as well as in a proof-of-concept study in patients with rheumatoid arthritis (RA). Results The mouse IL-1 receptor cross-reacts ...
157 CitationsSource
#1J. Jermany (Novartis)H-Index: 1
#2Janice Branson (Novartis)H-Index: 8
Last.Christiane Rordorf (Novartis)H-Index: 24
view all 5 authors...
This randomized, double-blind, placebo-controlled study evaluated the pharmacodynamic effects of concomitant low-dose aspirin and lumiracoxib in healthy subjects. Participants received lumiracoxib 400 mg once daily (n = 14) or placebo (n = 14) for 11 days, with concomitant low-dose aspirin (75 mg once daily) from days 5 to 11. Ex vivo pharmacodynamic assessments included assays of platelet aggregation and urinary thromboxane and prostacyclin metabolite profile. Arachidonic acid-stimulated platel...
11 CitationsSource